Literature DB >> 24870821

Clinical trials: More trials, fewer tribulations.

Michael Eisenstein.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24870821     DOI： 10.1038/509S55a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  6 in total

1.  Pathological complete response and accelerated drug approval in early breast cancer.

Authors:  Tatiana M Prowell; Richard Pazdur
Journal:  N Engl J Med       Date:  2012-05-30       Impact factor: 91.245

2.  Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).

Authors:  Nick Thatcher; Alex Chang; Purvish Parikh; José Rodrigues Pereira; Tudor Ciuleanu; Joachim von Pawel; Sumitra Thongprasert; Eng Huat Tan; Kristine Pemberton; Venice Archer; Kevin Carroll
Journal:  Lancet       Date:  2005 Oct 29-Nov 4       Impact factor: 79.321

3.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

4.  Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

Authors:  Yael P Mossé; Megan S Lim; Stephan D Voss; Keith Wilner; Katherine Ruffner; Julie Laliberte; Delphine Rolland; Frank M Balis; John M Maris; Brenda J Weigel; Ashish M Ingle; Charlotte Ahern; Peter C Adamson; Susan M Blaney
Journal:  Lancet Oncol       Date:  2013-04-16       Impact factor: 41.316

5.  Pancreatic cancer clinical trials and accrual in the United States.

Authors:  William A Hoos; Porsha M James; Lola Rahib; Anitra W Talley; Julie M Fleshman; Lynn M Matrisian
Journal:  J Clin Oncol       Date:  2013-08-19       Impact factor: 44.544

6.  Genome sequencing identifies a basis for everolimus sensitivity.

Authors:  Gopa Iyer; Aphrothiti J Hanrahan; Matthew I Milowsky; Hikmat Al-Ahmadie; Sasinya N Scott; Manickam Janakiraman; Mono Pirun; Chris Sander; Nicholas D Socci; Irina Ostrovnaya; Agnes Viale; Adriana Heguy; Luke Peng; Timothy A Chan; Bernard Bochner; Dean F Bajorin; Michael F Berger; Barry S Taylor; David B Solit
Journal:  Science       Date:  2012-08-23       Impact factor: 47.728
  6 in total
  1 in total

1.  Advancing Clinical Trials to Streamline Drug Development.

Authors:  Susan E Bates; Donald A Berry; Sanjeeve Balasubramaniam; Stuart Bailey; Patricia M LoRusso; Eric H Rubin
Journal:  Clin Cancer Res       Date:  2015-10-15       Impact factor: 12.531
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.